TICKERNERD
Menu
DHRDHRHealthcare · Diagnostics & Research

DHR Stock Forecast: Danaher Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$202
−0.71% on the day

The 26 Wall Street analysts covering Danaher Corp. hold a median 12-month price target of $230 — +13.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$142.3B
Ticker Nerd rank
71 / 100
Median analyst target
$230
Analysts covering
26
Total return, dividends reinvested
1W
−1.1%
1M
+1.7%
YTD
−11.2%
1Y
−3.0%
From 52W high
−16.0%
From 52W low
+25.3%
$162
$241
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DHR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Danaher Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Value
92
Quality
85
Revisions
73
Growth
71
Issuance
46
Momentum
45
Accruals
41
Size
2

Volatility (95): The share price has been relatively steady.

Accruals (41): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DHR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DHR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Oct 25Jan 26Apr 26Jul 26DHRHigh $310Median $230Low $195

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says26 analysts
22 Buy4 Hold0 Sell
Low $195Median $230High $310

The green dot is the last close — the median target sits +13.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
22 July 2026GuggenheimMaintainsBuy$235 → $200
22 July 2026RBC CapitalMaintainsOutperform$200 → $215
22 July 2026StifelMaintainsBuy$260 → $220
22 July 2026TD CowenMaintainsBuy$240 → $236
22 July 2026Wells FargoMaintainsEqual-Weight$212 → $195
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$232 → $230
11 June 2026Piper SandlerInitiatesNeutral—
3 June 2026HSBCMaintainsBuy—
2 June 2026Wolfe ResearchAssumesPeer Perform—
27 May 2026CitigroupDowngradeNeutral—
15 May 2026RBC CapitalReinstatesOutperform$200
23 Apr 2026Morgan StanleyMaintainsOverweight—
22 Apr 2026BairdMaintainsOutperform—
22 Apr 2026GuggenheimMaintainsBuy—
22 Apr 2026UBSMaintainsBuy—
22 Apr 2026Wells FargoMaintainsEqual-Weight—
17 Apr 2026BairdMaintainsOutperform—
14 Apr 2026BarclaysMaintainsOverweight—
13 Apr 2026Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DHR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DHR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.9%
Analysts raising
2
Analysts cutting
2
Fundamentals

Danaher Corp. (DHR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.1×

Cheaper than 22% of US stocks

Price / sales
5.7×

Cheaper than 23% of US stocks

Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
20.7×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
5.5%

Higher than 40% of US stocks

Earnings growth (YoY)
56.8%

Higher than 77% of US stocks

Gross margin
57.6%

Higher than 71% of US stocks

Operating margin
19.8%

Higher than 79% of US stocks

Net margin
15.9%

Higher than 79% of US stocks

Returns & dividend
Return on equity
7.6%

Higher than 58% of US stocks

Return on assets
3.9%

Higher than 71% of US stocks

Dividend yield
0.8%

Higher than 18% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DHR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
DHRDanaher Corp.$142.3B
71
TMOThermo Fisher Scientific, Inc.$221.0B
81
IDXXIDEXX Laboratories, Inc.$44.0B
93
NTRANatera, Inc.$42.8B
79
AAgilent Technologies, Inc.$42.1B
88
WATWaters Corp.$40.4B
49
IQVIQVIA Holdings, Inc.$39.0B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Danaher Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DHR news & analysis

Danaher: 2027 Growth Reacceleration Should Drive Upside

Seeking Alpha · 14 Aug 2026positive

Seeking Alpha rates Danaher a Buy, citing expected revenue growth reacceleration in 2027 as respiratory headwinds subside and bioprocessing shipments recover, along with a robust recovery in the Life Sciences segment showing 5.5% core growth and margin expansion.

Why it matters — The analysis points to improving pharma spending and biotech funding driving a Life Sciences recovery plus a reasonable valuation at a discount to its five-year average P/E, which investors would track for signs of sustained growth.

Diamond Hill Small-Mid Cap Fund Q2 2026 Portfolio Review

Seeking Alpha · 7 Aug 2026neutral

Diamond Hill's Small-Mid Cap Fund gained 9.71% in Q2 2026 versus a 20.26% increase for the Russell 2500 Index. The fund initiated a position in managed care provider Centene and sold shares of Wix.com due to slowing growth in its core business from AI-driven vibe coding.

Why it matters — This portfolio review does not mention Danaher Corp., so it offers no direct insight for DHR shareholders beyond general fund activity.

Aristotle Value Equity WM Q2 2026 Portfolio Performance

Seeking Alpha · 6 Aug 2026neutral

Aristotle Capital's Value Equity WM Composite returned 4.36% gross of fees (3.85% net) in Q2 2026. Corteva and Motorola Solutions were among the largest detractors during the period.

Why it matters — The portfolio performance and its detractors provide context for investors tracking value-oriented holdings, which may include companies relevant to Danaher Corp. watchers.

Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

PRNewsWire · 3 Aug 2026neutral

Danaher's Board of Directors appointed Julie Sawyer Montgomery as President, Chief Executive Officer, and a member of the Board, effective October 1, 2026. On that date, Rainer Blair will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition.

Why it matters — The announcement marks a leadership transition at Danaher's top executive role, which DHR watchers would follow for its implications on the company's future direction.

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

Seeking Alpha · 30 July 2026negative

Aristotle Capital's Global Equity Composite sold its position in Danaher during the second quarter of 2026. The fund's quarterly return of 6.92% gross (6.40% net) underperformed both the MSCI ACWI Index (14.93%) and the MSCI World Index (13.76%).

Why it matters — Danaher watchers would note that a major institutional investor exited its DHR position during a period when the broad market significantly outperformed the fund's returns.

FAQ

Frequently asked questions about DHR stock

What is the DHR stock price forecast for 2026-2027?

The 26 Wall Street analysts covering Danaher Corp. have a median 12-month price target of $230, with estimates ranging from $195 to $310. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DHR stock a buy right now?

Of the 26 analysts covering Danaher Corp., 22 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Danaher Corp. 71 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DHR?

As at 15 Aug 2026, Danaher Corp. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will DHR stock go up?

No one can know that. What the data says: the median 12-month target from 26 analysts implies +13.6% from the last close, and Ticker Nerd's factor model ranks Danaher Corp. 71 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DHR stock forecast for 2030?

No analyst covering Danaher Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $195 to $310 over the next 12 months.

How has DHR stock performed over the past year?

Danaher Corp. returned -3.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Danaher Corp. do?

Danaher Corporation is a global science and technology company focused on life sciences, biotechnology, diagnostics, and environmental and applied solutions. Danaher Corporation develops and manufactures instruments, consumables, software, and services used in laboratories, hospitals, research institutions, and industrial settings.

What is the latest news on DHR?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Danaher: 2027 Growth Reacceleration Should Drive Upside". Seeking Alpha rates Danaher a Buy, citing expected revenue growth reacceleration in 2027 as respiratory headwinds subside and bioprocessing shipments recover, along with a robust recovery in the Life Sciences segment showing 5.5% core growth and margin expansion.

Company

About Danaher Corp.

Danaher Corporation is a global science and technology company focused on life sciences, biotechnology, diagnostics, and environmental and applied solutions. Danaher Corporation develops and manufactures instruments, consumables, software, and services used in laboratories, hospitals, research institutions, and industrial settings. Its portfolio supports scientific research, clinical testing, bioprocessing, and quality control workflows, helping customers analyze biological samples, diagnose disease, and improve manufacturing processes. The company serves a broad range of markets, including healthcare, pharmaceutical development, academic research, and water and industrial applications. Danaher Corporation is known for operating through specialized business segments that provide highly technical tools and workflow solutions for professionals who need precision, reliability, and scalable performance across complex scientific and industrial environments.

CEO Mr. Rainer M. Blair · 58,000 employees · United States · https://www.danaher.com